O	0	6	Tsg101	Tsg101	NN	B-NP
O	7	9	is	be	VBZ	B-VP
O	10	21	upregulated	upregulate	VBN	I-VP
O	22	24	in	in	IN	B-PP
O	25	26	a	a	DT	B-NP
O	27	33	subset	subset	NN	I-NP
O	34	36	of	of	IN	B-PP
B-Cancer	37	45	invasive	invasive	JJ	B-NP
I-Cancer	46	51	human	human	JJ	I-NP
I-Cancer	52	58	breast	breast	NN	I-NP
I-Cancer	59	66	cancers	cancer	NNS	I-NP
O	67	70	and	and	CC	O
O	71	74	its	its	PRP$	B-NP
O	75	83	targeted	target	VBN	I-NP
O	84	98	overexpression	overexpression	NN	I-NP
O	99	101	in	in	IN	B-PP
O	102	112	transgenic	transgenic	JJ	B-NP
O	113	117	mice	mouse	NNS	I-NP
O	118	125	reveals	reveal	VBZ	B-VP
O	126	130	weak	weak	JJ	B-NP
O	131	140	oncogenic	oncogenic	JJ	I-NP
O	141	151	properties	property	NNS	I-NP
O	152	155	for	for	IN	B-PP
B-Cancer	156	163	mammary	mammary	JJ	B-NP
I-Cancer	164	170	cancer	cancer	NN	I-NP
O	171	181	initiation	initiation	NN	I-NP
O	181	182	.	.	.	O

O	184	192	Previous	Previous	JJ	B-NP
O	193	200	studies	study	NNS	I-NP
O	201	209	reported	report	VBD	B-VP
O	210	214	that	that	IN	B-SBAR
O	215	218	the	the	DT	B-NP
O	219	224	Tumor	Tumor	NN	I-NP
O	225	239	Susceptibility	Susceptibility	NN	I-NP
O	240	244	Gene	Gene	NN	I-NP
O	245	248	101	101	CD	I-NP
O	249	250	(	(	(	O
O	250	256	TSG101	TSG101	NN	B-NP
O	256	257	)	)	)	O
O	258	260	is	be	VBZ	B-VP
O	261	272	upregulated	upregulate	VBN	I-VP
O	273	275	in	in	IN	B-PP
O	276	284	selected	select	VBN	B-NP
O	285	290	human	human	JJ	I-NP
B-Cancer	291	303	malignancies	malignancy	NNS	I-NP
O	303	304	,	,	,	O
O	305	308	and	and	CC	O
O	309	312	the	the	DT	B-NP
O	313	323	expression	expression	NN	I-NP
O	324	326	of	of	IN	B-PP
O	327	336	exogenous	exogenous	JJ	B-NP
O	337	343	Tsg101	Tsg101	NN	I-NP
O	344	347	was	be	VBD	B-VP
O	348	357	suggested	suggest	VBN	I-VP
O	358	360	to	to	TO	I-VP
O	361	370	transform	transform	VB	I-VP
O	371	383	immortalized	immortalized	JJ	B-NP
B-Cell	384	395	fibroblasts	fibroblast	NNS	I-NP
O	396	398	in	in	IN	B-PP
O	399	406	culture	culture	NN	B-NP
O	406	407	.	.	.	O

O	408	410	To	To	TO	B-PP
O	411	415	date	date	NN	B-NP
O	415	416	,	,	,	O
O	417	420	the	the	DT	B-NP
O	421	430	potential	potential	JJ	I-NP
O	431	440	oncogenic	oncogenic	JJ	I-NP
O	441	451	properties	property	NNS	I-NP
O	452	454	of	of	IN	B-PP
O	455	461	Tsg101	Tsg101	NN	B-NP
O	462	466	have	have	VBP	B-VP
O	467	470	not	not	RB	I-VP
O	471	475	been	be	VBN	I-VP
O	476	484	examined	examine	VBN	I-VP
O	485	487	in	in	FW	B-ADVP
O	488	492	vivo	vivo	FW	I-ADVP
O	493	498	owing	owe	VBG	B-VP
O	499	501	to	to	TO	B-PP
O	502	505	the	the	DT	B-NP
O	506	510	lack	lack	NN	I-NP
O	511	513	of	of	IN	B-PP
O	514	525	appropriate	appropriate	JJ	B-NP
O	526	531	model	model	NN	I-NP
O	532	539	systems	system	NNS	I-NP
O	539	540	.	.	.	O

O	541	543	In	In	IN	B-PP
O	544	548	this	this	DT	B-NP
O	549	554	study	study	NN	I-NP
O	554	555	,	,	,	O
O	556	558	we	we	PRP	B-NP
O	559	563	show	show	VBP	B-VP
O	564	568	that	that	IN	B-SBAR
O	569	575	Tsg101	Tsg101	NN	B-NP
O	576	578	is	be	VBZ	B-VP
O	579	585	highly	highly	RB	I-VP
O	586	595	expressed	express	VBN	I-VP
O	596	598	in	in	IN	B-PP
O	599	600	a	a	DT	B-NP
O	601	607	subset	subset	NN	I-NP
O	608	610	of	of	IN	B-PP
B-Cancer	611	619	invasive	invasive	JJ	B-NP
I-Cancer	620	625	human	human	JJ	I-NP
I-Cancer	626	632	breast	breast	NN	I-NP
I-Cancer	633	640	cancers	cancer	NNS	I-NP
O	640	641	.	.	.	O

O	642	647	Based	Base	VBN	B-PP
O	648	650	on	on	IN	B-PP
O	651	655	this	this	DT	B-NP
O	656	667	observation	observation	NN	I-NP
O	667	668	,	,	,	O
O	669	671	we	we	PRP	B-NP
O	672	681	generated	generate	VBD	B-VP
O	682	685	the	the	DT	B-NP
O	686	691	first	first	JJ	I-NP
O	692	702	transgenic	transgenic	JJ	I-NP
O	703	708	mouse	mouse	NN	I-NP
O	709	714	model	model	NN	I-NP
O	715	719	with	with	IN	B-PP
O	720	721	a	a	DT	B-NP
O	722	730	targeted	target	VBN	I-NP
O	731	745	overexpression	overexpression	NN	I-NP
O	746	748	of	of	IN	B-PP
O	749	755	Tsg101	Tsg101	NN	B-NP
O	756	758	in	in	IN	B-PP
O	759	762	the	the	DT	B-NP
O	763	773	developing	develop	VBG	I-NP
B-Organ	774	781	mammary	mammary	JJ	I-NP
I-Organ	782	787	gland	gland	NN	I-NP
O	788	790	to	to	TO	B-VP
O	791	795	test	test	VB	I-VP
O	796	803	whether	whether	IN	B-SBAR
O	804	813	exogenous	exogenous	JJ	B-NP
O	814	820	Tsg101	Tsg101	NN	I-NP
O	821	823	is	be	VBZ	B-VP
O	824	831	capable	capable	JJ	B-ADJP
O	832	834	of	of	IN	B-PP
O	835	845	initiating	initiate	VBG	B-VP
O	846	859	tumorigenesis	tumorigenesis	NN	B-NP
O	859	860	.	.	.	O

O	861	867	Normal	Normal	JJ	B-NP
O	868	881	functionality	functionality	NN	I-NP
O	882	884	of	of	IN	B-PP
O	885	894	exogenous	exogenous	JJ	B-NP
O	895	901	Tsg101	Tsg101	NN	I-NP
O	902	905	was	be	VBD	B-VP
O	906	912	tested	test	VBN	I-VP
O	913	915	by	by	IN	B-PP
O	916	924	rescuing	rescue	VBG	B-VP
O	925	928	the	the	DT	B-NP
O	929	937	survival	survival	NN	I-NP
O	938	940	of	of	IN	B-PP
O	941	947	Tsg101	Tsg101	NN	B-NP
O	947	948	-	-	HYPH	B-NP
O	948	957	deficient	deficient	JJ	I-NP
B-Cell	958	965	mammary	mammary	JJ	I-NP
I-Cell	966	976	epithelial	epithelial	JJ	I-NP
I-Cell	977	982	cells	cell	NNS	I-NP
O	983	985	in	in	IN	B-PP
O	986	997	conditional	conditional	JJ	B-NP
O	998	1006	knockout	knockout	NN	I-NP
O	1007	1011	mice	mouse	NNS	I-NP
O	1011	1012	.	.	.	O

O	1013	1016	The	The	DT	B-NP
O	1017	1031	overexpression	overexpression	NN	I-NP
O	1032	1034	of	of	IN	B-PP
O	1035	1041	Tsg101	Tsg101	NN	B-NP
O	1042	1050	resulted	result	VBD	B-VP
O	1051	1053	in	in	IN	B-PP
O	1054	1063	increased	increase	VBN	B-NP
O	1064	1079	phosphorylation	phosphorylation	NN	I-NP
O	1080	1082	of	of	IN	B-PP
O	1083	1086	the	the	DT	B-NP
O	1087	1096	epidermal	epidermal	JJ	I-NP
O	1097	1103	growth	growth	NN	I-NP
O	1104	1110	factor	factor	NN	I-NP
O	1111	1119	receptor	receptor	NN	I-NP
O	1120	1123	and	and	CC	O
O	1124	1134	downstream	downstream	JJ	B-NP
O	1135	1145	activation	activation	NN	I-NP
O	1146	1148	of	of	IN	B-PP
O	1149	1152	MAP	MAP	NN	B-NP
O	1153	1160	kinases	kinase	NNS	I-NP
O	1160	1161	.	.	.	O

O	1162	1169	Despite	Despite	IN	B-PP
O	1170	1172	an	an	DT	B-NP
O	1173	1181	increase	increase	NN	I-NP
O	1182	1184	in	in	IN	B-PP
O	1185	1188	the	the	DT	B-NP
O	1189	1199	activation	activation	NN	I-NP
O	1200	1202	of	of	IN	B-PP
O	1203	1208	these	these	DT	B-NP
O	1209	1215	signal	signal	NN	I-NP
O	1216	1227	transducers	transducer	NNS	I-NP
O	1227	1228	,	,	,	O
O	1229	1232	the	the	DT	B-NP
B-Organ	1233	1240	mammary	mammary	JJ	I-NP
I-Organ	1241	1246	gland	gland	NN	I-NP
O	1247	1249	of	of	IN	B-PP
O	1250	1257	females	female	NNS	B-NP
O	1258	1268	expressing	express	VBG	B-VP
O	1269	1278	exogenous	exogenous	JJ	B-NP
O	1279	1285	Tsg101	Tsg101	NN	I-NP
O	1286	1295	developed	develop	VBN	B-VP
O	1296	1304	normally	normally	RB	B-ADVP
O	1305	1315	throughout	throughout	IN	B-PP
O	1316	1319	the	the	DT	B-NP
O	1320	1332	reproductive	reproductive	JJ	I-NP
O	1333	1338	cycle	cycle	NN	I-NP
O	1338	1339	.	.	.	O

O	1340	1342	In	In	IN	B-PP
O	1343	1348	aging	age	VBG	B-NP
O	1349	1356	females	female	NNS	I-NP
O	1356	1357	,	,	,	O
O	1358	1361	the	the	DT	B-NP
O	1362	1376	overexpression	overexpression	NN	I-NP
O	1377	1379	of	of	IN	B-PP
O	1380	1386	Tsg101	Tsg101	NN	B-NP
O	1387	1393	seemed	seem	VBD	B-VP
O	1394	1396	to	to	TO	I-VP
O	1397	1405	increase	increase	VB	I-VP
O	1406	1409	the	the	DT	B-NP
O	1410	1424	susceptibility	susceptibility	NN	I-NP
O	1425	1427	of	of	IN	B-PP
B-Tissue	1428	1435	mammary	mammary	JJ	B-NP
I-Tissue	1436	1445	epithelia	epithelia	NN	I-NP
O	1446	1452	toward	toward	IN	B-PP
O	1453	1462	malignant	malignant	JJ	B-NP
O	1463	1477	transformation	transformation	NN	I-NP
O	1477	1478	.	.	.	O

O	1479	1486	However	However	RB	B-ADVP
O	1486	1487	,	,	,	O
O	1488	1493	owing	owe	VBG	B-VP
O	1494	1496	to	to	TO	B-PP
O	1497	1500	the	the	DT	B-NP
O	1501	1505	long	long	JJ	I-NP
O	1506	1513	latency	latency	NN	I-NP
O	1514	1516	of	of	IN	B-PP
B-Cancer	1517	1522	tumor	tumor	NN	B-NP
O	1523	1532	formation	formation	NN	I-NP
O	1533	1536	and	and	CC	O
O	1537	1540	the	the	DT	B-NP
O	1541	1549	sporadic	sporadic	JJ	I-NP
O	1550	1560	occurrence	occurrence	NN	I-NP
O	1561	1563	of	of	IN	B-PP
O	1564	1568	bona	bona	FW	B-NP
O	1569	1573	fide	fide	FW	I-NP
B-Cancer	1574	1581	mammary	mammary	JJ	I-NP
I-Cancer	1582	1589	cancers	cancer	NNS	I-NP
O	1589	1590	,	,	,	O
O	1591	1593	we	we	PRP	B-NP
O	1594	1602	conclude	conclude	VBP	B-VP
O	1603	1607	that	that	IN	B-SBAR
O	1608	1611	the	the	DT	B-NP
O	1612	1618	Tsg101	Tsg101	NN	I-NP
O	1619	1626	protein	protein	NN	I-NP
O	1627	1630	has	have	VBZ	B-VP
O	1631	1635	only	only	RB	B-NP
O	1636	1640	weak	weak	JJ	I-NP
O	1641	1650	oncogenic	oncogenic	JJ	I-NP
O	1651	1661	properties	property	NNS	I-NP
O	1661	1662	.	.	.	O

O	1663	1670	Instead	Instead	RB	B-PP
O	1671	1673	of	of	IN	I-PP
B-Cancer	1674	1680	cancer	cancer	NN	B-NP
O	1681	1691	initiation	initiation	NN	I-NP
O	1691	1692	,	,	,	O
O	1693	1695	it	it	PRP	B-NP
O	1696	1698	is	be	VBZ	B-VP
O	1699	1708	therefore	therefore	RB	B-ADVP
O	1709	1715	likely	likely	JJ	B-ADJP
O	1716	1720	that	that	IN	B-SBAR
O	1721	1727	Tsg101	Tsg101	NN	B-NP
O	1728	1733	plays	play	VBZ	B-VP
O	1734	1735	a	a	DT	B-NP
O	1736	1740	more	more	RBR	I-NP
O	1741	1752	predominant	predominant	JJ	I-NP
O	1753	1757	role	role	NN	I-NP
O	1758	1760	in	in	IN	B-PP
O	1761	1764	the	the	DT	B-NP
O	1765	1776	progression	progression	NN	I-NP
O	1777	1779	of	of	IN	B-PP
O	1780	1781	a	a	DT	B-NP
O	1782	1788	subset	subset	NN	I-NP
O	1789	1791	of	of	IN	B-PP
O	1792	1805	spontaneously	spontaneously	RB	B-VP
O	1806	1813	arising	arise	VBG	I-VP
B-Cancer	1814	1820	breast	breast	NN	B-NP
I-Cancer	1821	1828	cancers	cancer	NNS	I-NP
O	1828	1829	.	.	.	O

